WuXi Advanced Therapies

WuXi Advanced Therapies is owned by HiberCell. HiberCell has a direct presence in 2 countries.

HiberCell has 7 subsidiaries including Genuity Science, WuXi Advanced Therapies and WuXi AppTec.

View the org chart displaying its 2 main executives

Most searched biographies at WuXi Advanced Therapies

• David Chang, Chief Executive Officer
• Jennifer Cheung, Vice President, Quality Assurance and Regulatory ...

Create your alert
to follow the executive moves at WuXi Advanced Therapies.

HiberCell has 2,276 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by WuXi Advanced Therapies

Social media about WuXi Advanced Therapies

• WuXi Advanced Therapies on Wikipedia, Google News & Yahoo Finance
• WuXi Advanced Therapies on LinkedIn, Twitter & YouTube

Contact by email its executives including David Chang

Call WuXi Advanced Therapies at +1 651...

View the org chart

Register to receive your alert

Report an error